Cytochrome P450 activity in rheumatoid arthritis patients during continuous IL-6 receptor antagonist therapy.

Eur J Clin Pharmacol · 2023 · PMC10663184 · PMID 37831074

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

Based on the primary endpoint midazolam metabolic ratio, we observe a slight trend towards a weak increase in CYP3A4 activity in patients with rheumatoid arthritis after 3 weeks of anti-IL-6R therapy.

also in 1,563 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.